Skip to main content
Fig. 5 | Journal of Experimental & Clinical Cancer Research

Fig. 5

From: Expanding anti-CD38 immunotherapy for lymphoid malignancies

Fig. 5

Potent effector function of CD38-CAR T cells against T-ALL and NKTCL in vivo. A Schematic of CAR T cells treatment protocol. NSG mice were intravenously injected with 5 × 106 fLuc-transduced T-ALL cells (MOLT-4). After 7 days, the mice were treated with 8 × 106 CD38-CAR T cells or control T cells (n = 5). B A serial of representative bioluminescent imaging showing leukemia progression/regression in mice. C Kinetics of leukemia progression in mice treated with CD38-CAR T cells or control T cells measured by bioluminescent imaging. D Survival curve for each experimental group. E Schematic of CAR T cells treatment protocol. NSG mice were subcutaneously injected with 5 × 106 NKTCL cells (YT). After 18 or 20 days, the mice were treated with 8 × 106 CD38-CAR T cells or control T cells (n = 5). F Mean tumor growth kinetics with the treatment of CD38-CAR T cells or control T cells. G Images of CD38-CAR T cells or control T cells-treated tumor harvested on 33rd day after implantation. Tumor weight G was measured per group (n = 5)

Back to article page